

**Supplementary Table 2.** Baseline characteristics of patients included in sensitivity analysis examining predictors of no recanalization on imaging obtained 6 months after diagnosis (n=447)

Characteristic	No recanalization (n=57)	Complete or partial recanalization (n=390)
<b>Patient characteristics</b>		
Age (yr)	55.6±5.5	42.3±15.5
Female sex	25 (43.9)	272 (69.7)
<b>Race</b>		
White	45 (78.9)	291 (75.0)
Black	7 (12.3)	47 (12.1)
Asian	2 (3.5)	17 (4.4)
<b>Ethnicity</b>		
Non-Hispanic	52 (91.2)	348 (89.7)
Hispanic	5 (8.8)	40 (10.3)
Body mass index ≥30	21 (36.8)	163 (41.8)
<b>CVT risk factors</b>		
Personal history of VTE or PE	6 (10.5)	32 (8.2)
Family history of VTE	4 (7.0)	53 (13.7)
Recent head trauma	4 (7.0)	35 (9.0)
Recent mastoiditis or sinusitis	8 (14.0)	30 (7.7)
Recent lumbar puncture	2 (3.5)	19 (4.9)
12 weeks postpartum	0 (0.0)	14 (3.6)
Oral contraceptive pill use	7 (12.3)	131 (34.2)
Active smoking	4 (7.0)	34 (8.8)
<b>Clinical presentation</b>		
Headache	43 (75.4)	323 (82.8)
Encephalopathy	9 (15.8)	52 (13.3)
Papilledema	6 (10.9)	49 (13.5)
Focal deficit	13 (27.1)	114 (34.0)
Seizure	12 (21.1)	89 (22.8)
Coma	0 (0.0)	5 (1.3)
FVL and/or PTG*	4 (10.5)	32 (10.6)
<b>Imaging findings</b>		
<b>CVT involvement</b>		
Either superficial, deep, or cortical vein	56 (98.2)	336 (86.2)
Superficial and deep vein involvement	1 (1.8)	54 (13.8)
Venous infarct	12 (21.1)	92 (23.6)
Cerebral edema	10 (17.5)	106 (27.2)
Intracranial hemorrhage	14 (24.6)	140 (35.9)
<b>Hospital course</b>		
Symptom onset to anticoagulation initiation (day)	5 (2–29)	5 (2–14)
<b>Oral anticoagulant medication<sup>†</sup></b>		
Warfarin	39 (68.4)	264 (67.7)
Dabigatran	20 (35.1)	123 (31.5)
Rivaroxaban	5 (8.8)	35 (9.0)
Apixaban	2 (3.5)	30 (7.7)
Duration of oral anticoagulation (day)	209 (181–210)	149 (90–190)
Duration of treatment to imaging (day) <sup>‡</sup>	209 (200–210)	157 (93–196)

Data are presented as mean±standard deviation, number (%), or median (interquartile range). The totals of some categorical variables may not match the group populations due to missing data.

CVT, cerebral venous thrombosis; VTE, venous thromboembolism; PE, pulmonary embolism; FVL, Factor V Leiden; PTG, prothrombin gene G20210A mutation. \*% represent the number of patients with a positive result (numerator) over the number of patients who had available data or underwent the specific test (denominator); <sup>†</sup>Numbers do not sum to group totals because patients that received both warfarin and a direct oral anticoagulant at different time points were included under both medications; <sup>‡</sup>First image that shows signs of recanalization; in cases of no recanalization, we used the date when the most recent image was obtained.